Retargeting OVs to enter cells via tumor-specific receptors is primarily highlighted, wherein the insertion of corresponding genes into the OVs enables the expressions of certain ligands capable of preferably binding with the specific receptors (e.g., CD38, EGFR, and RGD) overexpressed on tumor cells [40,52]. The gene discussed is CD38; the disease is neoplasm.